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ABSTRACT
INTRODUCTION: Osteoarthritis (OA) is the leading cause of 
disability in elderly people. Several non-invasive solutions 
have been proposed with varying success rates. Recently, 
new therapeutic approaches, such as the use of minimally 
manipulated tissue products, have gained increasing 
popularity.  The purpose of this study was to investigate the 
safety and feasibility of a single intra-articular injection of 
autologous, microfragmented adipose tissue in patients 
with knee OA. 
METHODS: The study was performed as a prospective 
cohort study. Microfragmented adipose tissue was obtained 
using a minimal manipulation technique (Lipogems). The 
safety of the procedure was evaluated by recording the type 
and incidence of any adverse events at three months. The 
clinical outcomes were determined using the Knee injury 
and Osteoarthritis Outcome Score (KOOS) scale at three, six 
and 12 months of follow-up. 
RESULTS: Twenty patients were included in the study and 
all participated in the follow-up. Only one adverse event was 
registered; a patient complaint of cosmetic changes to the 
abdominal subcutaneous tissue. The improvements in KOOS 
were significant at all follow-up. At one year, KOOS pain had 
improved by 14 points, symptoms by seven, activity of daily 
living by 13, sports by 19 and quality of life by 15. 
CONCLUSIONS: The intra-articular injection of autologous, 
microfragmented adipose tissue for treatment of knee OA 
seems safe. Randomised controlled trials are needed to 
elucidate the efficacy of the treatment. 
TRIAL REGISTRATION: This study was registered in 
ClinicalTrials.gov (NCT02697682).
FUNDING: none.
Osteoarthritis (OA) of the knee is a destructive joint 
disease causing degeneration of cartilage, damage to 
the underlying bone and morphological changes to the 
joint [1]. It is a major public health concern due to the 
increased life expectancy of the ageing population [2]. 
No approved medical treatment that reverses the mor-
phological changes currently exists. Conventional treat-
ment includes physiotherapy, pain killers, braces and, 
in the end-stage, surgical knee replacement [3].
During the past decade, researchers have explored 
the regenerative potential of mesenchymal stem cells 
derived from adipose tissue in the treatment of OA [4, 
5]. The complex regulatory issues applying for enzym-
atically treated and/or expanded cells have led to the 
development of minimally manipulated tissue [6]. 
Lipogems is one such system where the adipose tissue 
is mechanically microfragmented and washed until free 
of pro-inflammatory oil and blood residues. The result-
ing product is composed of small intact adipose tissue 
clusters (250-650 microns) containing pericytes re-
tained within an intact stromal vascular niche. Peri-
cytes are cells situated at the external wall of the capil-
laries, which detach after injury or inflammation from 
the capillaries and convert into activated regenerative 
mesenchymal stem cells [7]. The activated pericytes 
are said to release exosomes filled with regenerative 
factors that allow for tissue repair and regeneration 
[7]. The product is safe (obtained the US Food and 
Drug Agency’s approval in 2014), and in case series it 
has been demonstrated to be effective in the treatment 
of various pathologies including knee, ankle, hip and 
shoulder OA [8], but level-one evidence is lacking. The 
Lipogems system is being introduced worldwide these 
years, why it is of utmost importance to investigate the 
safety, feasibility and efficiency of the product. A small 
safety study investigating injection with Lipogems in 26 
knees was published in November 2018 showing no se-
vere adverse events, but the study did not investigate 
donor site morbidity [9]. 
The purpose of the present study was to investigate 
short-term safety issues and the feasibility of using au-
tologous, microfragmented adipose tissue processed 
with the Lipogems system for treatment of knee OA.
METHODS
The study was an independent, non-profit prospective 
cohort study following the Strengthening the Reporting 
of Observational Studies in Epidemiology guidelines 
for reporting of observational studies.  
The study was performed at the outpatient clinic of 
the Orthopaedic Department at Zealand University 
Hospital, Koege, Denmark, in the period from April 2016 
to July 2017 with inclusion and treatment of patients 
spanning the first three months of the study period.
Study design and population
Patients referred to the department who were suffering 
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from long-lasting knee pain (more than six months) 
and OA of the knee (Kellgren-Lawrence grade 1-4) 
were eligible for inclusion if aged 18-70 years, expected 
to be able to attend rehabilitation and post-examin-
ations, able to speak and understand Danish and able 
to provide their informed consent. Patients were ex-
cluded from the study if they had varus or valgus mal-
alignment of the knee exceeding five degrees, rupture 
of to the cruciate ligaments of the knee, a BMI above 35 
kg/m2 or an American Society of Anesthesiologists 
score higher than or equal to three. Patients were in-
formed of the study verbally and in writing and, on an 
informed basis without any pressure, allowed 24 hours 
of reflection before written consent was obtained.
Patients were treated with a 10-ml intra-articular 
injection with autologous, microfragmented adipose 
tissue prepared using the Lipogems system.
Harvesting of the adipose tissue
Harvesting of adipose tissue was performed under ster-
ile conditions in the operating theatre. The patient was 
positioned in the supine position, and an area just 
below the umbilicus of approximately 8 cm (cranio-
caudally) × 20 cm (laterally) was marked on the skin 
with a surgical marker. Under sterile conditions, the 
adipose tissue was prepared for harvesting by injection 
of a suspension of 20 ml carbocain 1%, 200 ml isotonic 
saline, 0.2 ml adrenaline and 10 mmol bicarbonate 
using a disposable 17-G blunt cannula connected to a 
luer-lock 60-ml syringe. The fat was then harvested 
using a 13-G blunt cannula connected to a Vaclock 20-
ml syringe. At the end of the procedure, the skin was 
closed with a plaster. 
Processing of the adipose tissue  
with the Lipogems device
The harvested fat was immediately processed in the 
Lipogems processing kit (Lipogems International Spa, 
Italy), a disposable device that progressively reduces 
the size of the adipose tissue clusters while eliminating 
oily substances and blood residues with pro-inflamma-
tory properties [8, 10]. The entire process, carried out 
in one surgical step, was performed in immersion in a 
physiological saline solution minimising any traumatic 
action on cell products. The resulting microfragmented 
tissue was collected in a 60-ml syringe and positioned 
for decanting the excessive saline solution. Finally, the 
product was transferred into ten 1-ml syringes.
Microfragmented adipose tissue injection
Microfragmented adipose tissue was injected under 
sterile conditions with the patient in the supine pos-
ition on an examination bench with the affected knee 
stretched. The superior pole of the patella was palpa-
ted, and the femoral condyle was marked with a sur-
gical marker. The suprapatellar recess was located by 
ultrasound, and a 21-G syringe was introduced in the 
suprapatellar recess.
Follow-up visits and outcome measures
Patients were followed-up at three, six and 12 months 
by a designated project nurse. All data were collected 
by the nurse through patient-reported questionnaires.
The primary outcome was safety at three months, 
assessed by recording any adverse event at three 
months. An adverse event was defined as any event 
caused by the treatment leading to a less preferable 
situ ation for the patient. Patients were screened for  
donor site morbidity (infection, swelling, pain) and  
injection site morbidity (infection, swelling, pain). 
Secondary outcomes were adverse events after six and 
12 months and improvements in the clinical outcomes 
measured by the Knee injury and Osteoarthritis 
Outcome Score (KOOS) [11]. The KOOS holds 42 
items in five separately scored subscales: Pain, Symp-
toms, Function in daily living, Function in Sport and 
Recreation, and knee-related Quality of Life. The five 
patient-relevant subscales of KOOS were scored separ-
ately and transformed into a 0-100 scale, with zero rep-
resenting extreme knee problems and 100 representing 
no knee problems. A change of ten points or more was 
considered clinically relevant [11].
Sample size and power
Being a pilot study, 20 patients were included based on 
logistical considerations and the sample sizes of pre-
vious pilot studies. No power calculation was made.
Statistical analysis
Descriptive data were presented as means and standard 
deviations for continuous data and as number of pa-
TABLE 1
Baseline data. Patient demographics and Knee injury and 
 Osteoarthritis Outcome Scores. 
Mean ± SD
Age, yrs 49 ± 9
Weight, kg 89 ± 22












ADL = activities of daily living; KOOS = Knee injury and Osteoarthritis Out-
come Score; QoL = quality of life; SD = standard deviation. 
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tients for categorical data. Density plots of data were 
performed and visually evaluated for normality. Com-
parison of baseline KOOS scores at three, six and 12 
months was performed using repeated measurement 
ANOVA. The level of significance was set at p < 0.05. 
Trial registration: This study was registered in Clinical-
Trials.gov (NCT02697682).
RESULTS
Twenty patients were included in the study from April 
to July 2016, all of whom participated in the one-year 
follow-up. Baseline data are presented in Table 1. 
One patient complained of cosmetic irregularity at 
the donor site due to harvesting of too much tissue at 
one location. Secondarily, this was corrected by a plas-
tic surgeon where after the patient obtained a cosmet-
ically satisfactory result. Patients reported moderate to 
severe pain at the donor site in the weeks following the 
procedure, but no persistent pain at the donor site was 
reported at the three-month follow-up (Table 1). 
 A statistically significant improvement in KOOS 
was seen in all subscales. At the 12-month follow-up, 
pain improved 14 points, symptoms seven points, activ-
ities of daily living (ADL) 13 points, sports 19 points 
and quality of life (QoL) 15 points. Ten points or more 
is considered a clinically relevant improvement [11], 
and as such, only four of the five subscales (pain, ADL, 
sports and QoL) showed a clinically important im-
provement (Figure 1 and Figure 2). At this time, 15 
out of 20 patients would go for the procedure again, 
two would not and three did not know. Two of the pa-
tients who did not respond to the treatment have later 
responded positively to surgical treatment by lengthen-
ing of the lateral retinaculum. Both were diagnosed as 
having patellofemoral pain based on hyper pressure 
due to a tight lateral retinaculum.
DISCUSSION
No safety issues were raised in relation to the Lipogems 
system. One patient complained of cosmetic changes to 
the abdominal subcutaneous tissue, but this must be 
considered a minor complication and was probably due 
to lack of experience with lipoaspiration on the part of 
the orthopaedic surgeon harvesting the fat. The sur-
geon was trained and supervised for the first five cases 
by an experienced consultant plastic surgeon, but still a 
learning curve effect must be expected. Pain during the 
procedure was light (visual analogue scale (VAS) 1.8) 
but increased in the week after the treatment where 
pain levels rose to VAS 4.4 before declining to VAS 1  
after one month and VAS 0.2 after three months. These 
findings are in line with those reported by Panchal et al 
[9] and support future investigation of the efficacy of 
the procedure. 
FIGURE 1
Mean (95% confidence interval) improvement in Knee injury and Osteoarthritis Outcome Score 
(KOOS) subscales from baseline to three, six and 12 months of follow-up. A change of ten 













ADL = activities of daily living; QoL = quality of life. 
FIGURE 2
The five subscales of the Knee injury and Osteoarthritis Outcome Score at baseline and at  

















ADL = activities of daily living; QoL = quality of life.
) Statistically significant improvement from baseline.
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Liposuction is one of the most commonly performed 
aesthetic procedures and few complications are re-
ported, but the literature is very sparse concerning do-
nor site morbidity in patients with minimal lipoaspir-
ation like the one being performed in the present study. 
In 2017, Comella and colleagues reported on safety is-
sues after abdominal liposuction and autologous stem 
cell therapy [12]. They reported 3.4% adverse events 
including soreness at the site of harvest. No other com-
plications were reported, but no systematic investiga-
tion of donor site morbidity was described in the paper. 
Possibly, complications are underestimated and under-
reported by caregivers. In larger body-contouring pro-
cedures, minor wound complications have been re-
ported in 6% of cases and fatal complications in 19-20 
per 100,000 [13, 14]. It seems reasonable to conclude 
that minimal lipoaspiration like the one performed in 
the present study is safe but not pain free. Patients 
should be informed that pain and discomfort will be 
present at the time of the procedure and one month  
afterwards, with discomfort peaking one week after the 
procedure. 
No adverse events where found in the treated knees 
or at the injection sites. This correlates well with the lit-
erature where no superficial infections or septic arthri-
tis have been reported after injection with microfrag-
mented adipose tissue [14]. Comparing with other 
types of knee injection, the risk of septic arthritis is 
probably very limited, but present. Infection rates after 
injection with corticosteroids or hyaluronate are not re-
ported in the literature, but case reports exist and, in a 
Korean study, an increase in septic arthritis rates was 
attributed to increased use of intra-articular agents 
[15]. 
No serious adverse effects like infection or tumour 
formation have been observed in the treatment of OA 
with mesenchymal stem cells or minimally manipu-
lated tissue products [16]. More than 17,000 scientific 
articles have been published reporting on the treatment 
of more than 320,000 patients [17]. No severe safety 
issues have been raised [18]. As such, it seems reason-
able to conclude that local intra-articular injection of 
autologous, microfragmented adipose tissue in the 
knee is a feasible and safe procedure. 
The patients experienced a statistically significant 
and clinically relevant improvement in KOOS on four of 
the five subscales; however, the effect might be ex-
plained by natural variation in the disease or a placebo 
effect as the study included no control group and no 
blinding was possible. 
One randomised clinical trial (RCT) has been pub-
lished that studied treatment of OA in the knee with 
minimally manipulated tissue [19].  It was a prospec-
tive, single-blind, placebo-controlled trial including 25 
patients with bilateral OA of the knee. The patients 
were randomised to receive bone marrow aspirated 
from the iliac crest into one knee and saline placebo 
into the other. There was a dramatic and statistically 
significant pain relief in both knees after one and six 
months, but no difference between the knees indicating 
that placebo treatment with saline worked just as well 
as the bone marrow aspirate. Assessing the pain litera-
ture more broadly, sham surgical procedures for pain 
intervention have been shown to yield significant pain 
improvements. The effect was largest within the first 
month of sham surgery but remained present at six 
months [20].
The main limitation of the study was the small sam-
ple size rendering it impossible to investigate for safety 
of rare complications. Another limitation was the 
method used for implantation of the microfragmented 
adipose tissue in the supra patellar pouch of the knee. 
As ultrasonography was not routinely performed, a risk 
of misplacement of the graft outside the knee joint was 
present. 
Despite these limitations, we can conclude that the 
treatment of knee OA with intra-articular injection with 
autologous, microfragmented and minimally manipu-
lated adipose tissue seems safe. High-quality RCTs are 
needed to elucidate the efficacy of the treatment. 
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